assessed the efficacy and safety of PD-1 inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study and found that a blocking antibody targeting PD-1 had an obvious antitumor effect in NSCLC patients and an acceptable side-effect profile (22). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.